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FGF21 improves the metabolic profile of obese ani-
mals through its actions on adipocytes. To elucidate
the signaling network responsible for mediating
these effects, we quantified dynamic changes in
the adipocyte phosphoproteome following acute
exposure to FGF21. FGF21 regulated a network of
821 phosphosites on 542 proteins. A major FGF21-
regulated signaling node was mTORC1/S6K. In
contrast to insulin, FGF21 activated mTORC1 via
MAPK rather than through the canonical PI3K/AKT
pathway. Activation of mTORC1/S6K by FGF21 was
surprising because this is thought to contribute to
deleterious metabolic effects such as obesity and in-
sulin resistance. Rather, mTORC1 mediated many of
the beneficial actions of FGF21 in vitro, including
UCP1 and FGF21 induction, increased adiponectin
secretion, and enhanced glucose uptake without
any adverse effects on insulin action. This study pro-
vides a global view of FGF21 signaling and suggests
that mTORC1 may act to facilitate FGF21-mediated
health benefits in vivo.INTRODUCTION
Fibroblast growth factor 21 (FGF21) extends lifespan and exerts
numerous health benefits, including improved insulin sensitivity
and reduced adiposity and hepatic steatosis (Kharitonenkov
et al., 2005, 2007; Zhang et al., 2012). FGF21mediates its effects
by stimulating fibroblast growth factor receptor (FGFR) 1/2 in
complex with the coreceptor b-klotho (Ogawa et al., 2007).
Knockout of FGFR1 or b-klotho in adipocytes, or knockout of
b-klotho in CNS, prevents FGF21-mediated improvements in in-
sulin sensitivity and reductions in adiposity (Adams et al., 2012;
Bookout et al., 2013; Ding et al., 2012; Owen et al., 2014), whileCel
This is an open access article under the CC BY-Ninhibition of b-klotho in the liver prevents FGF21-mediated
reduction in hepatic steatosis (Gong et al., 2016). Antibody-
mediated activation of FGFR1c-b-klotho, which activates
FGF21 signaling in adipocytes without detectable effects in liver
or CNS, recapitulates the beneficial metabolic actions of FGF21
(Kolumam et al., 2015). This suggests that FGF21 signaling in
adipocytes is crucial for FGF21’s actions. In adipocytes,
FGF21 stimulates browning, adiponectin secretion, and glucose
uptake (Fisher et al., 2012; Holland et al., 2013; Lin et al., 2013),
and these effects are thought to underpin the beneficial effects of
FGF21.
Althoughmuch is known about FGF21 actions, there aremajor
gaps in our understanding of the mechanisms underlying these
effects. In particular, the intracellular signaling pathways that
coordinate FGF21’s effects are unclear. Given that protein
phosphorylation networks process hormonal inputs into meta-
bolic responses (Humphrey et al., 2015b), we therefore sought
to quantify the phosphoproteome of adipocytes acutely stimu-
lated with FGF21 to provide a systems view of the signaling
networks underlying the cellular response to this hormone.RESULTS AND DISCUSSION
FGF21-Regulated Phosphorylation in Adipocytes
To map the FGF21 signaling network in adipocytes, 3T3-L1 ad-
ipocytes underwent stable isotope labeling by amino acids in cell
culture (SILAC) (Ong et al., 2002). Triple SILAC-labeled cells were
stimulated with FGF21 to generate a time series spanning 30 s to
30min (Olsen et al., 2006). Phosphopeptides were enriched, and
the phosphoproteome was analyzed by quantitative mass spec-
trometry (MS) in biological triplicates (Figure 1A). In total, we
identified 15,687 phosphorylation sites on 4,583 distinct pro-
teins, and 11,706 of these (median localization probability
0.994) were accurately localized to a single residue (Class 1
sites, localization probability R 0.75) (Figure 1A). A previous
study quantified 1,186 phosphosites and identified 130 sites
regulated by FGF21 (Muise et al., 2013). Of the phosphorylation






Figure 1. Phosphoproteomic Analysis of
FGF21 RevealsmTORC1 Is aMajor Signaling
Node
(A) Experimental design of the FGF21 phospho-
proteome. SILAC-labeled 3T3-L1 adipocytes were
serum starved for 1.5 hr and treated with FGF21
over a time course. Proteins were extracted
and digested with trypsin. Peptides were fraction-
ated by SCX chromatography, and phosphopep-
tides were enriched using TiO2 chromatography.
Phosphopeptide fractions were analyzed by MS.
The number of phosphorylated proteins and
phosphosites identified, quantified, and FGF21
regulated (adj. p < 0.05, fold change < 0.67 or fold
change > 1.5) are shown.
(B) FGF21-mediated phosphorylation of FGFR1
(Y653, Y654) and MAPK1 (T183, Y185).
(C) Number of significantly regulated phosphosites
at each time point (adj. p < 0.05, fold change < 0.67
or fold change > 1.5).
(D) Phosphorylation profile of the kinase activation
site (blue) and substrates (yellow).
(E) Sequence logos for phosphorylation sites that
were FGF21 regulated at 2 and 5 min.
(F) Mice were intraperitoneally injectedwith FGF21,
and white adipose tissue was collected at indi-
cated time points. Fat was immunoblotted for
indicated proteins and stained for total protein by
Sypro Ruby as a loading control. Immunoblots
were quantified and normalized to total protein and
average maximal response (n = 6, mean ± SEM,
one-way ANOVA, *p < 0.01).study, FGF21 significantly regulated 12.5% (821) by <0.67-fold
or >1.5-fold (adjusted [adj.] p < 0.05) (Figure 1A), greatly expand-
ing the known FGF21 signaling network in adipocytes. FGF21
signaling was initiated by tyrosine phosphorylation of FGFR1,
closely followed by phosphorylation of ERK1 and 2 (Figure 1B).
Following these events, the number of significantly FGF21-regu-
lated phosphosites increased from just a few at 2 min to >550
after 5 min (Figure 1C).
We next searched for kinases that propagate FGF21 signaling
downstream of ERK. In response to FGF21, 56 kinases were
phosphorylated, 13 of whichwere phosphorylated on known acti-
vation sites. To identify activated kinases, we applied clustering
and directional analysis to the temporal profiles of kinase sub-
strates in our phosphoproteomics data (Domanova et al., 2016;
Yang et al., 2014). Kinases with enhanced activity in the FGF21-
regulated phosphoproteome included ERK1/2, mTORC1, S6K,
AKT, CHEK, PKA, and CDK2 (Figure S1).
mTORC1 and S6K Activation Are Prominent Features of
FGF21 Signaling in Adipocytes
mTORC1 activates S6K, and these kinases are widely regarded
as important regulators of metabolism (Dibble and Cantley,30 Cell Reports 17, 29–36, September 27, 20162015). Our phosphoproteomics data sug-
gest that mTORC1 and S6K are key nodes
in FGF21 signaling. The mTORC1 sub-
strate and activation site of S6K1 (S444/
427) was the third most highly phosphory-lated kinase activation site (4.5- and 2.6-fold change at 5 min)
after ERK2 T183/Y185 (13.7- and 8.0-fold change at 5 min) and
FGFR1 Y653/Y654 (9.2-fold change at 2 min). In addition, at
the peak of mTORC1 and S6K activity (5–30 min), FGF21 sig-
naling activity became markedly amplified, and there was an
enrichment of substrates containing mTOR, ERK, and S6K min-
imal consensus motifs (Figures 1C–1E). To confirm activation of
mTORC1/S6K by FGF21 in vivo, we injected mice with FGF21
and removed adipose tissue at different times. Phosphorylation
of ERK at its activation site (T183/Y185) was increased at 5 min,
and mTORC1/S6K activity was elevated after 30 min, as as-
sessed by phosphorylation of the S6K substrate 40S ribosomal
protein S6 (RPS6) (S235/S236) (Figure 1F). Another study re-
ported that chronic FGF21 administration (10 days) in mice in-
hibits mTORC1 activity in the liver (Gong et al., 2016). This may
therefore reflect the development of FGF21 resistance in the liver
under these conditions or differential signaling in these cell
types.
Intersection of FGF21 and Insulin Signaling Networks
mTORC1 and S6K are also central to insulin signaling. However,
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Figure 2. Comparison of MAPK, Akt, and
mTORC1 Signaling in Response to FGF21
and Insulin
(A) Comparison of FGF21 (23 nM) and insulin
(100 nM) phosphoproteomes (Humphrey et al.,
2013) after 30 and 20 min of stimulation, respec-
tively. The Venn diagram indicates overlap of
significantly regulated phosphorylation sites (adj.
p < 0.05, fold change < 0.67 or fold change > 1.5).
(B) KinasePA. The x and y axes show calculated
Stouffer’s statistics for FGF21- and insulin-stimu-
lated kinase activation, respectively. The open
circle (AKT) indicates amanually curated substrate
list used for KinasePA analysis.
(C) 3T3-L1 adipocytes were serum starved and
then treated with 0.5 nM insulin or 23 nMFGF21 for
indicated times. Cell lysates were immunoblotted
for the ERK activation site (ERK1 T183/Y185), Akt
substrates (PRAS40 T246 and AS160 T642), and
an indicator of mTORC1 activation (S6 S235/
S236). Immunoblots were quantified and scaled
(n = 3, mean ± SEM).
(D–F) 3T3-L1 adipocytes were serum starved for
1.5 hr, pretreated with 500 nM rapamycin for
30 min where indicated, and then treated with
10 nM insulin or 23 nM FGF21. (D) Glucose uptake
was assessed by uptake of [3H]2DOG (n = 6 for
FGF21, n = 9 for insulin, mean ± SEM, one-way
ANOVA, *p < 0.01 versus basal). (E) Lipolysis was
assessed via release of glycerol into culture media
after stimulation with the indicated dose of
isoproterenol. Data were normalized to the
maximum basal value (n = 3, mean ± SEM, two-
way ANOVA, *p < 0.01 versus respective basal at
the same isoproterenol dose). (F) Protein synthesis
was assessed by incorporation of [3H]leucine into
protein. Data are normalized to the maximal value
(n = 3, mean ± SEM, one-way ANOVA, *p < 0.01).
(G) 3T3-L1 adipocytes were serum starved,
treated with Akt inhibitors (MK2206) or MAPK in-
hibitor (U0126) for 30 min, and then treated with
23 nM FGF21 for 30 min. Cell lysates were im-
munoblotted with indicated antibodies. Immuno-
blots were quantified and normalized to tubulin
(loading control) and FGF21-treated cells. (n = 3,
mean ± SEM, one-sample t test, *p < 0.01).negative feedback loop that triggers insulin resistance and
increased adiposity (Copps and White, 2012; Hsu et al., 2011;
Um et al., 2004; Yu et al., 2011). A comparison of the FGF21
and insulin phosphoproteomes (Humphrey et al., 2013) revealed
that FGF21 signaling was in general slower than insulin but that
28%of FGF21-regulated phosphosites seen after 20min of stim-
ulation were also regulated by insulin after 20 min (Figure 2A),
suggesting a convergence of later signaling events. Using a ki-
nase perturbation analysis (KinasePA, http://rp-www.cs.usyd.
edu.au/yangpy/software/KinasePA.html) (Yang et al., 2016),
we found that at these time points, insulin and FGF21 most
strongly regulated the substrates of S6K, followed by ERK2,
ERK1, RSK, and Akt (Figure 2B). However, Akt was more
robustly activated by insulin, and when a manually curated sub-
set of higher-confidence Akt substrates was used for this
analysis, this difference was even greater (Figure 2B). These
data suggest that in adipocytes, FGF21 and insulin share themTORC1 and S6K network branches but may be differentiated
by the robust early activation of Akt that occurs with insulin.
FGF21 Weakly Activates Akt but Robustly
Activates MAPK
We next compared the effects of FGF21 on the Akt andmitogen-
activated protein kinase (MAPK) pathways with a physiological
dose of insulin (0.5 nM) (Winzell and Ahre´n, 2004). FGF21 had
a transient and minor effect on Akt signaling compared to the
physiological dose of insulin, whereas its stimulation of the
MAPK pathway was 11-fold more potent than that observed
with insulin (Figure 2C). Hence, this shows that the effects of
FGF21 on MAPK are highly specific, and under physiological
conditions, insulin may have a relatively minor effect on MAPK
signaling in adipocytes.
Next, we examined whether the modest activation of Akt by
FGF21 was biologically relevant. In contrast to insulin (10 nM),Cell Reports 17, 29–36, September 27, 2016 31
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Figure 3. mTORC1 Mediates the Beneficial
Actions of FGF21 in Adipocytes
(A) FGF21-regulated phosphorylation sites are
depicted on IRS1 and IRS2 (adj. p < 0.05, fold
change > 1.5 at any time point). The y axis repre-
sents log2 FC after 30 min of FGF21 stimulation
(n = 3, mean ± SEM).
(B) 3T3-L1 adipocytes were treated with 10 nM
insulin, 23 nM FGF21, or both for 16 hr, serum
starved for 2 hr, and then assayed for glucose
uptake without (basal) or with (10 nM) insulin for
30 min (n = 5, mean ± SEM, two-way ANOVA, *p <
0.01 versus insulin-stimulated control). Bottom:
insulin-sensitive glucose uptake (D insulin-basal)
is shown. Data are normalized to control (n = 5,
mean ± SEM, one-sample t test, *p < 0.01).
(C–F) 3T3-L1 adipocytes (C) or subcutaneous ad-
ipocytes differentiated in vitro (D–F) were treated
for 16 hr with 23 nM FGF21, 10 nM insulin, 500 nM
rapamycin (R), or 10 mM U0126 (U). (C) Cells were
serum starved and glucose uptake was assessed
using [3H]2DOG (n = 3). (D) Adiponectin secreted
into cell culture media was detected by immuno-
blotting, and immunoblots were quantified and
normalized to basal (n = 4). (E and F) FGF21 and UCP1 mRNAs were determined and normalized to basal (n = 8 for control and FGF21-treated cells, n = 5 for
insulin-treated cells). Data presented are mean ± SEM. *p < 0.05 by two-way ANOVA versus FGF21-treated cells. #p < 0.01 one-way ANOVA versus untreated
cells or for (D) one sample t test. NS, non-significant.acute FGF21 treatment had no significant effect on glucose up-
take or lipolysis (Figures 2D and 2E), two Akt-dependent pro-
cesses (Tan et al., 2015). In contrast, protein synthesis, which
is largely an mTORC1-mediated process, was stimulated by
both FGF21 and insulin, and this was blocked by the mTORC1
inhibitor rapamycin (Figure 2F). Collectively, these data indicate
that FGF21 and insulin elicit distinct actions in adipocytes, partly
because of differential signaling through Akt and MAPK.
FGF21 Activates mTORC1 via MAPK
The insulin receptor, like most tyrosine kinase receptors, acti-
vates mTORC1 through PI3K/Akt, whereas others, such as the
epidermal growth factor (EGF) receptor, use the MAPK pathway
(Carriere et al., 2011; Ma et al., 2005). To determine whether
FGF21-stimulated mTORC1 activity was MAPK or Akt depen-
dent, we incubated cells with specific inhibitors of either Akt
(MK-2206) or MEK (U0126), the kinase immediately upstream
of ERK (Figure 2G). Only the MEK inhibitor prevented FGF21-
mediated RPS6 and S6K phosphorylation, demonstrating that
mTORC1 activation by FGF21 is dependent on MAPK, and not
Akt, activity (Figure 2G).
FGF21-Induced mTORC1 Activation Does Not Lead to
Insulin Resistance
It has been suggested that hyperinsulinemia induces insulin
resistance via negative feedback pathways involving phosphor-
ylation of insulin receptor substrate (IRS) proteins (Shah and
Hunter, 2006; Shah et al., 2004; Um et al., 2004). However,
some studies have questioned the relevance of serine/threo-
nine (Ser/Thr) IRS phosphorylation in mediating insulin resis-
tance (Hoehn et al., 2008). FGF21 stimulated IRS1 and IRS2
phosphorylation on sites previously implicated in insulin resis-
tance, including S302, S307, and S522, on IRS1 (Figure 3A)32 Cell Reports 17, 29–36, September 27, 2016(Shah and Hunter, 2006). To determine whether this might
induce insulin resistance, adipocytes were incubated with
FGF21 (23 nM) for 16 hr. However, in contrast to chronic insulin
treatment, which significantly impaired insulin-stimulated
glucose uptake, chronic treatment with FGF21 had no signifi-
cant impact on insulin action (Figure 3B). We also cotreated
cells with FGF21 and insulin to investigate whether FGF21
could overcome the inhibitory effect of chronic insulin expo-
sure. FGF21 did not improve insulin sensitivity in cells exposed
to chronic insulin (Figure 3B). Rather FGF21 increased basal
glucose uptake, likely due to increased GLUT1 expression
(Palfreyman et al., 1992). These findings indicate that FGF21-
mediated Ser/Thr IRS phosphorylation does not cause insulin
resistance in adipocytes.
mTORC1 Mediates FGF21-Induced Glucose Uptake,
Adiponectin Secretion, and UCP1 Expression
Next, we questioned whether mTORC1 may mediate the benefi-
cial actions of FGF21. FGF21 is thought to induce weight loss
and insulin sensitivity by stimulating glucose uptake, browning,
and adiponectin secretion in adipocytes. To investigate whether
these actions aremediated bymTORC1 andMAPK, we inhibited
these kinases with rapamycin or U0126, respectively. Prolonged
rapamycin treatment can also inhibit mTORC2. However, it is un-
likely that this accounts for the effects of rapamycin on FGF21
action in adipocytes, because there was no significant increase
in mTORC2 activity with FGF21, as demonstrated by measure-
ment of Akt phosphorylation at the mTORC2 site S473 (Fig-
ure S2). Thus, rapamycin treatment likely reflects a selective
effect on mTORC1.
Treatment of adipocytes with FGF21 for 16 hr increased
glucose uptake by 3-fold, and this was blocked with either
rapamycin or U0126 (Figure 3C). To assess browning and
Figure 4. FGF21 Signaling Network in
Adipocytes
FGF21 binding to the FGFR1/bKlotho complex
triggers receptor auto-phosphorylation and sub-
sequent activation of the MAPK pathway and then
the mTORC1/S6K pathway. The Akt pathway is
only weakly stimulated in response to FGF21. The
mTORC1/S6K pathway next stimulates adipo-
nectin secretion, glucose uptake, and UCP1 and
FGF21 expression. Regulation of transcription is
key for these events. FGF21 signals to many
transcription factors.adiponectin secretion, we used primary adipocytes, which were
differentiated from a stromal vascular fraction (SVF) isolated
from mouse subcutaneous adipose tissue. Primary adipocytes
incubated with FGF21 for 16 hr increased adiponectin secretion
by 40%, and this was inhibited by rapamycin (Figure 3D), while
inhibition by U0126 was variable. Next we measured UCP1
mRNA levels as an index of adipocyte browning. Both rapamycin
and U0126 inhibited FGF21-induced UCP1 expression (Fig-
ure 3E). In the same cells, FGF21 also induced FGF21 gene
expression, and this was rapamycin sensitive (Figure 3F). Incu-
bation of adipocytes with U0126 increased FGF21 expression
in the absence of FGF21 treatment. Collectively, these data
demonstrate that activation of mTORC1 is required for the meta-
bolically beneficial effects of FGF21, specifically glucose uptake,
browning, and adiponectin secretion in adipocytes, and to stim-
ulate an autocrine feedback loop through increased FGF21
expression. Consistent with our findings, several studies have
found that mTORC1 mediates upregulation of UCP1 and adipo-
cyte browning in response to either cold exposure or b-adren-
ergic agonists (Liu et al., 2016; Tran et al., 2016) and hyper-acti-
vation of mTORC1 in liver and muscle increases circulating
FGF21 and weight loss (Cornu et al., 2014; Guridi et al., 2015).
This raises the question of whether other hormones that acti-
vate mTORC1 (Figure 2B), most notably insulin, could mimic
the effects of FGF21 in adipocytes. Chronic incubation of adipo-Cell Rcytes with insulin also induced UCP1
mRNA expression, but it did not signifi-
cantly increase FGF21mRNA expression
(Figures 3E and 3F). These data suggest
that stimuli aside from FGF21 that acti-
vate mTORC1may also upregulate genes
associated with adipocyte browning.
We therefore predict that insulin and
mTORC1 may upregulate FGF21 and
UCP1 to restrain obesity. FGF21 actions
may also be enhanced during obesity by
high basal mTORC1 activity, and it would
be of major interest for future studies to
investigate whether mTORC1 mediates
FGF21’s whole-body effects, such as
weight loss and insulin sensitivity in vivo.
FGF21 Signaling Network
Here we performed an unbiased sys-
tems analysis of FGF21 signaling. Ourdata reveal that activation of the FGFR1/bKlotho complex trig-
gers receptor tyrosine auto-phosphorylation, followed by acti-
vation of the MAPK pathway and subsequent mTORC1/S6K
pathway activity (Figure 4). The mTORC1/S6K pathway leads
to adiponectin secretion, glucose uptake, and UCP1 and
FGF21 expression (Figures 3C–3F). Transcriptional regulation
is key for these events; FGF21 upregulates not only UCP1
and FGF21 mRNA but also adiponectin and GLUT1 mRNA
(Ge et al., 2011; Lin et al., 2013). In support of a major effect
of FGF21 on transcription, many transcriptional regulators
were phosphorylated in response to FGF21 in our phosphopro-
teomics data (Figure 4). These include CRTC2, a CREB coacti-
vator that stimulates PGC1a transcription and mitochondrial
biogenesis (Wu et al., 2006); MORC2a, which is required for dif-
ferentiation of 3T3-L1 preadipocytes and for expression of
genes involved in de novo lipogenesis (Sa´nchez-Solana et al.,
2014); and NR3C1, a glucocorticoid receptor that regulates
the expression of GLUT1 (Sakoda et al., 2000). These data
are valuable resources for identifying key effectors of FGF21
action.
Our findings that mTORC1 is involved in metabolic processes
that are implicated in reversing insulin resistance during FGF21
treatment contrast with its proposed role in hyperinsulinemia.
By comparing our data with previous phosphoproteomics
studies performed in different metabolic tissues and contexts,eports 17, 29–36, September 27, 2016 33
it is becoming increasingly clear that cells recruit only a specific
subset of kinases that integrate and process signals by
hormones or stimuli to determine distinct metabolic outputs
(Hoffman et al., 2015; Humphrey et al., 2015a; Lundby et al.,
2013). Our data demonstrate the importance of systems-wide
analysis of signaling networks in determining how cells process
inputs to determine biological outcomes. These data provide
insights into the mechanism of FGF21 actions and have
implications for treatments designed to improve metabolic
disorders, including the use of rapamycin as a health-promot-
ing agent.
EXPERIMENTAL PROCEDURES
For complete details, see the Supplemental Experimental Procedures.
Animals
Mice were fed a standard lab chow diet and group-housed on a 12 hr light/dark
cycle with free access to food and water. At 12 weeks of age, mice were in-
jected intraperitoneally with either FGF21 (10 mg/kg) or saline as vehicle con-
trol. Mouse experiments were approved by The University of Sydney Animal
Ethics Committee.
FGF21 Phosphoproteomics Analysis
3T3-L1 adipocytes underwent SILAC, were serum starved, and were treated
with 23 nM FGF21 for 30 s, 2 min, 5 min, and 30 min. Peptides were digested
with trypsin (Promega), fractionated by strong cation exchange (SCX), and en-
riched for phosphopeptides by TiO2. Labeled peptides were analyzed by MS,
and raw files were processed in MaxQuant.
Cell Assays
Preadipocytes from the SVF were isolated from white subcutaneous fat
tissue from 8- to 10-week-old C57BL/6 mice (Sugii et al., 2011). To assess
2-deoxyglucose (2DOG) uptake, cells were incubated in glucose-free Krebs
Ringer buffer (KRP), stimulated with 10 nM insulin for 15 min, exposed to
0.25 mCi/L [3H]-labeled 2-deoxyglucose ([3H]2DOG) (PerkinElmer) in 50 mM
unlabeled 2DOG for 5min, and radioactivity assessed in cell lysates. To assess
lipolysis, cells were incubated in KRP supplemented with 3.5% free fatty
acid BSA (Sigma-Aldrich). Cells were treated with or without isoproterenol, in-
sulin, or FGF21 for 1 hr as indicated. Aliquots of media were assayed for glyc-
erol content using Sigma glycerol reagent. To assess protein synthesis, adipo-
cytes were incubated in leucine-free DMEM (Sigma-Aldrich) supplemented
with [3H]-labeled leucine ([3H]leucine) (5 mCi/mL) (PerkinElmer) and FGF21
or insulin for 1 hr. Protein was precipitated from cell homogenates with 10%
trichloroacetic acid (TCA) and radioactivity assessed in TCA-insoluble frac-
tions of cell homogenates. All measurements were normalized to protein
concentrations.
Statistical Analysis
The t tests or ANOVAs were performed, as indicated, in GraphPad Prism
v.6.01 for Windows. Statistical analysis of proteomics data is described in
detail in the Supplemental Experimental Procedures.
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